The European Medicines Agency is exploring how companies developing cancer drugs can better evaluate the cardiovascular (CV) safety of their products, given that around one in every three patients develops CV toxicity due to oncological treatments and these cases are likely to grow.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?